AhR Antagonists

Cat.No.	Product Name	Information	Product Use Citations
S2858	Stemregenin 1 (SR1)	StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor with IC50 of 127 nM in a cell-free assay.	Nature, 2026, 10.1038/s41586-026-10295-z Clin Cancer Res, 2026, 32(9):1846-1859 Int J Biol Sci, 2026, 22(7):3788-3806
S7711	CH-223191	CH-223191 is a potent and specific aryl hydrocarbon receptor (AhR) antagonist with IC50 of 30 nM.	Exp Mol Med, 2026, 58(3):848-863 Cells, 2025, 14(8)605 Chem Biol Interact, 2025, 412:111478
S8995	BAY 2416964	BAY 2416964 (compound 192) is a potent and orally active antagonist of aryl hydrocarbon receptor (AhR) with IC50 of 341 nM. This compound has the potential in the treatment of solid tumors.	Scientific Reports, March 8, 2024, 5731 NAR Genomics and Bioinformatics, April 24, 2025, lqaf052 Nature, 2026, 10.1038/s41586-026-10295-z
S6560	PDM2	PDM2 is a potent and selective aryl hydrocarbon receptor (AhR) antagonist.	Cancer Cell Int, 2021, 21(1):538 Cancer Cell International, 2021, 538
S6926	GNF351	GNF351 is a potent antagonist of aryl hydrocarbon receptor (AHR). This compound interacts directly with the AHR ligand binding pocket and competes with a well-characterized photoaffinity AHR ligand for binding to the AHR with IC50 of 62 nM.	Frontiers in Pharmacology, 2021, 655281 Front Pharmacol, 2021, 12:655281 Frontiers in Pharmacology, 07 June 2021, 655281
S0155	PDM-11	PDM-11 is a derivative of resveratrol that exhibits stronger antagonist affinity for arylhydrocarbon receptors (AhR) than resveratrol, without any affinity for the estrogen receptor.
S1177	PD 98059	PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.	Anticancer Research, September 2017, 4911-4918 Cancer Research, September 15, 2019, 4650-4664 Journal of Clinical Medicine, June 24, 2019, 900
1 2